Compare IRS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
Current Price
Current Price
| Metric | IRS | MGTX |
|---|---|---|
| Founded | 1943 | 2015 |
| Country | Argentina | United States |
| Employees | 1392 | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 909.1M |
| IPO Year | N/A | 2018 |
| Metric | IRS | MGTX |
|---|---|---|
| Price | $15.49 | $13.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.57 |
| AVG Volume (30 Days) | 118.0K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 9.85% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.66 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $10.87 | $6.62 |
| 52 Week High | $19.14 | $15.35 |
| Indicator | IRS | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 62.91 |
| Support Level | $15.50 | $7.21 |
| Resistance Level | $15.96 | N/A |
| Average True Range (ATR) | 0.61 | 0.95 |
| MACD | -0.11 | 0.14 |
| Stochastic Oscillator | 34.65 | 53.96 |
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.